Navigation Links
Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
Date:2/17/2009

Studies presented at the 19th Conference of the Asian Pacific Association for the Study of the Liver (APASL) Demonstrated Favorable Pharmacokinetics and Significant Reduction in Viral Load

TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, today announced results from international Phase I and II clinical trials evaluating a controlled release version of nitazoxanide in the treatment of chronic hepatitis C virus (HCV) infection. In the phase II study in treatment-naive patients infected with HCV genotype 4, 82% (n=17) and 100% (n=16) of patients receiving low and high doses of controlled release nitazoxanide, respectively, experienced undetectable serum HCV RNA (<12 IU/mL) after 12 weeks of combination therapy with peginterferon and ribavirin.

The data, part of Romark's OPTIMA HCN (OPTImizing MAnagement of Hepatitis C with Nitazoxanide) development program, were presented this weekend in an oral presentation at the 19th Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Hong Kong. The presentation titled "Controlled Release Tablet Improves Pharmacokinetics, Viral Kinetics and Tolerability of Nitazoxanide for Treatment of Chronic Hepatitis C," abstract FP052, was given by Emmet B. Keeffe, M.D. of the Romark Institute for Medical Research, Tampa, FL.

"We continue to be encouraged by the results of the ongoing nitazoxanide clinical development program," said Jean-Francois Rossignol, M.D., Director of the Romark Institute for Medical Research and discoverer of nitazoxanide. "These data show that controlled release nitazoxanide exhibits favorable pharmacokinetics and tolerability, and - in combination with the standard of care therapy - robust antiviral activity in a small number of patients with HCV genotype 4. We look forward to reporting interim data from our U.S. studies evalua
'/>"/>

SOURCE Romark Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
2. Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
3. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
4. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
5. Copan Announces the Appointment of Bob Cooper as Vice President of Business Development in the Pacific Rim
6. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
7. Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
8. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
9. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
10. Savient Announces Appointment of David Gionco as Chief Financial Officer
11. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 Nerium International, ... is in the spotlight again. Nerium will showcase ... its NeriumFirmTM Body Contouring Cream to Hollywood’s elite ... Creations during the 66th Primetime Emmy® Awards. , ... extract, third-party clinical trials show that NeriumAD night ...
(Date:8/21/2014)... LYNBROOK, N.Y. , Aug. 21, 2014 /PRNewswire/ ... a biopharmaceutical company developing first in class collagenase-based ... histolyticum or CCH) in the U.S. and XIAPEX ... statistically significant results from a randomized, double-blind Phase ... of cellulite, or edematous fibrosclerotic panniculopathy. The results ...
(Date:8/21/2014)... An international research team including DESY scientists has observed ... The team reports in the journal Science ... lattices inside the nanodroplets. It is the first time ... in larger samples of what is known as superfluid ... exceeded our best expectations," says Andrey Vilesov of the ...
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the ... of His Majesty Willem-Alexander, King of the Netherlands, has ... of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant ... King will take part in the Grand Opening Ceremony ... a.m.-12:20 p.m. and tour the plant. POET-DSM is a ...
Breaking Biology Technology:Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3
... increasing global demand for health ... economics and market access support, BOSTON, Oct. ... Adam Barak as Vice President., Mr. Barak brings 16 ... pricing and reimbursement strategies,for drugs, medical devices, and diagnostics in ...
... Also Announces Completion of Enrollment in U.S. Phase ... Hepatitis C,Genotype 1, TAMPA, Fla., Oct. 28 ... announced the presentation of studies,of nitazoxanide at the ... the Study of Liver Diseases (AASLD), also known ...
... - Laureate To Manufacture Tolera,s Monoclonal Antibody ... 28 Laureate Pharma, Inc., a,full-service biopharmaceutical ... it has entered into a cGMP contract ... company that,develops and offers targeted therapies and ...
Cached Biology Technology:Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability 2Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc. 2
(Date:8/22/2014)... presented at the 29th Annual International Papillomavirus Conference ... Therapeutics Inc. combats three types of human papillomavirus, ... all cervical cancer. , When tested in several ... of HPV-16, HPV-18 and HPV-11 cells, according to ... who presented the findings at the Seattle conference. ...
(Date:8/22/2014)... discoveries in basic and clinical research and technological ... a complex offensive spanning multiple fronts. , Work ... could help find new and more selective therapies ... targets a specific enzyme overexpressed in certain cancersand ... brain tumours. , Chemistry professor Christopher Cairo and ...
(Date:8/22/2014)... consumers will finally be able to purchase fuel cell ... zero-emissions vehicles, most of the cars will run on ... contributes to global warming. , Now scientists at Stanford ... an ordinary AAA battery to produce hydrogen by water ... two electrodes that split liquid water into hydrogen and ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3
... to provide a detailed picture of how and when ... in animals, including humans. The evolutionary origins of ... of phylogenetic relationships among the earliest opsin-possessing animals. ... and colleagues at NUI Maynooth performed a computational analysis ...
... , Inc. (OTCBB: BLFS), a leading developer, manufacturer and ... and cryopreservation freeze media for cells and ... announced the Company,s novel biopreservation technology is being used ... it the leading choice in the emerging, high growth ...
... you fitter than ever mentally fit. In a ... of high-intensity interval training. At the end, their cognitive functions ... had improved significantly, says Dr. Martin Juneau, director of ... to people who exercise, they say they feel sharper. Now ...
Cached Biology News:BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies 2BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies 3BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies 4Exercise is smart for your heart - and makes you smarter 2
Sterile, Cell culture tested...
... have been many modifications to the original formulas ... solutions still play an important role in tissue,culture. ... pH and osmotic balance in the medium and ... inorganic ions, is as valuable today as when ...
A substrate for all AChE-based EIA kits....
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
Biology Products: